Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2015 Sep;59(9):5819-23. doi: 10.1128/AAC.00273-15. Epub 2015 Jun 8.

Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.

Author information

1
Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom karin.seifert@lshtm.ac.uk.
2
Mologen AG, Berlin, Germany.
3
Animal Health and Veterinary Laboratories Agency, New Haw, Surrey, United Kingdom School of Veterinary Medicine, University of Surrey, Guildford, Surrey, United Kingdom.
4
Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Abstract

Combination therapies for leishmaniasis, including drugs and immunomodulators, are one approach to shorten treatment courses and to improve the treatment of complex manifestations of the disease. We evaluated a novel T-cell-epitope-enriched DNA vaccine candidate (LEISHDNAVAX) as host-directed immunotherapy in combination with a standard antileishmanial drug in experimental visceral leishmaniasis. Here we show that the DNA vaccine candidate can boost the efficacy of a single suboptimal dose of liposomal amphotericin B in C57BL/6 mice.

PMID:
26055371
PMCID:
PMC4538505
DOI:
10.1128/AAC.00273-15
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center